For information regarding COVID-19 and updated visitation guidelines, please click here.

Cardiology Clinical Trials

Call for more information: 770-219-9010

Explore our current clinical trials for cardiology:

[Updated: 11/22/2019]

Electrophysiology 

LSS of 4SITE Study

Closed to Enrollment

The goal of this study is to evaluate, document and report on the appropriate clinical performance, the long-term reliability and the functional integrity of the 4-SITE Lead/Header System.

LSS of 4SITE Study Clinical Trial

NGMC Investigator: Dr. Ahn

Optimum Registry

Closed to Enrollment

This registry will evaluate the chronic clinical performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optimum insulation material. 

Optimum Registry Clinical Trial

NGMC Investigator: Dr. Ahn

AMPLATZER™ AMULET™ Left Atrial Appendage (LAA) Occluder Trial

Closed to Enrollment

The  AMPLATZER™ Amulet™  Left Atrial Appendage (LAA) Occluder Trial is designed to evaluate the safety and effectiveness of the Amulet device compared to the approved WATCHMAN LAA closure device in patients with non-valvular atrial fibrillation and at a high risk for bleeding.   Eligible patients will be randomized to receive wither the Amulet device or the WATCHMAN device.

AMPLATZER™ AMULET™ Left Atrial Appendage (LAA) Clinical Trial

NGMC Investigator: Dr. Gambhir

Smart Registry

Closed to Enrollment

A registry to learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better response than others.

Smart Registry Clinical Trial

NGMC Investigator: Dr. Sayar

Heart Failure

CONNECT HF

Enrolling

A large scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of 2 quality improvement (QI) initiatives compared with usual care on heart failure (HF) outcomes and HF quality of care metrics at 1 year after discharge for participants hospitalized with acute HF and reduced ejection fraction (EF). 

CONNECT HF Clinical Trial

NGMC Investigator: Dr. Egolum

Interventional

Absorb III & IV

Closed to Enrollment

A prospective randomized, single-blind, multi-center trial to evaluate the safety and effectiveness of the Absorb BVS System compared to XIENCE in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.

Absorb III & IV Clinical Trial

NGMC Investigator: Dr. Ryan Whitney

AEGIS II - Investigate the Efficacy & Safety of CSL112 in Subjects with Acute Coronary Syndrome

Enrollment Pending

CSL112 is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in acute coronary syndrome (ACS) patients diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation

AEGIS II Clinical Trial

NGMC Investigator: Dr. Ghasemzadeh

Eclipse Study

Enrolling

This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).

Eclipse Clinical Trial

NGMC Investigator: Dr. Ghasemzadeh

Harmonee Study

Closed to Enrollment

A multi-center, single-blind, randomized, Clinical Evaluation of the Combination Sirolimus-Eluting and anti-CD34 Antibody-Coated (COMBO) Stent for Coronary Lesions.  

Harmonee Clinical Trial

NGMC Investigator: Dr. Patel

Leaders Free II BioFreedon Pivotal Study

Closed to Enrollment

This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study in high bleeding risk patients.

Leaders Free II BioFreedon Pivotal Clinical Trial

NGMC Investigator: Dr. Patel

National Cardiogenic Shock Initiative

Enrolling

Assess the feasibility of whether outcomes in cardiogenic shock can be improved by using standardized best practices including inserting Impella© early and before PCI.

National Cardiogenic Shock Initiative Clinical Trial

NGMC Investigator: Dr. Patel

Xience 28

Enrolling

Evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with XIENCE.

Xience 28 Clinical Trial

NGMC Investigator: Dr. Ghasemzadeh

Xience Short DAPT

Closed to Enrollment

A prospective, multicenter, single-arm study designed to assess   the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding undergoing percutaneous coronary intervention with any approved XIENCE family of Stent Systems. 

Xience Short DAPT Clinical Trial

NGMC Investigator: Dr. A. Patel

Interventional/Peripheral Vascular

Disrupt PAD III

On Hold for Enrollment

A multi-center, single blind, randomized (1:1) study of Lithoplasty treatment used in combination with DCB versus standard balloon angioplasty used in combination with DCB to treat moderate and severely calcified femoropopliteal arteries.

Disrupt PAD III Clinical Trial

NGMC Investigator: Dr. Patel

Transcend Study

Closed to Enrollment

Demonstrate the safety & efficacy of the SurVeil DCB for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.

Transcend Clinical Trial

NGMC Investigator: Dr. Ghasemzadeh

Copyright ©2020 Northeast Georgia Health System, Inc. | 743 Spring Street Gainesville, GA 30501 | (770) 219-9000